ChemoCentryx's stock jumps 80% after receiving FDA approval for vasculitis drug

3 years ago 350

Shares of ChemoCentryx Inc. CCXI, +5.43% soared 80.3% successful premarket trading connected Friday aft the institution said that it had received support from the Food and Drug Administration for its ANCA-associated vasculitis therapy. The institution said this is the archetypal caller cause to dainty the uncommon autoimmune illness successful a decade. ChemoCentryx's banal slipped 68.3% this year, portion the broader S&P 500 SPX, +0.83% is up 16.1%.

Read Entire Article

ChemoCentryx's stock jumps 80% after receiving FDA approval for vasculitis drug

Related

How Can We Boost Our Online Influence with Expert Guest Post...

J.P. Morgan’s 2 Stock Picks With Over 80% Upside Potential

A 27-year-old truck driver just became Robinhood’s first big...

AT&T Stock Has Fallen to a Multi-Decade Low. Why It Could Be...

Trending

Popular

$1 Million in Fines Proposed Over Nitrogen Leak That Killed ...

Biden Officials Now Expect Vulnerable Americans to Need Boos...

First match in Tokyo called off due to COVID

USA's explosive $90m lawsuit hits Olympics

Vacuuming DNA from air can reveal which animals are present ...